BeOne Medicines (NASDAQ:ONC) Stock: Insider Chan Henry Lee Sells 1,115 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Lee sold 1,115 shares of the firm’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $375.00, for a total transaction of $418,125.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, August 11th, Chan Lee sold 2,666 shares of BeOne Medicines stock. The stock was sold at an average price of $360.00, for a total transaction of $959,760.00.
• On Thursday, July 30th, Chan Lee sold 1,044 shares of BeOne Medicines stock. The shares were sold at an average price of $323.69, for a total transaction of $337,932.36.
• On Wednesday, July 8th, Chan Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44.

BeOne Medicines Stock Down 0.2%

NASDAQ:ONC traded down $0.70 during trading hours on Friday, reaching $358.07. The company’s stock had a trading volume of 474,002 shares, compared to its average volume of 306,091. The stock has a 50 day moving average price of $353.31 and a two-hundred day moving average price of $315.93. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The company has a market capitalization of $39.31 billion, a P/E ratio of 63.04 and a beta of 0.61. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $253.95 and a 12 month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The business had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.66 billion. Equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 EPS for the current fiscal year.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: JPMorgan raised its price target on BeOne Medicines to $445 from $425 and maintained an “overweight” rating, implying substantial upside from recent levels. This reinforces the broader Wall Street consensus, which remains “Buy.” JPMorgan raises BeOne Medicines price target
• Positive Sentiment: Investor’s Business Daily said BeOne shares are approaching potential buy points, highlighting continued momentum in BRUKINSA, the company’s blockbuster cancer drug, which generated $1.2 billion in second-quarter sales. BeOne Medicines poised to hit early buy points
• Neutral Sentiment: BeOne’s latest quarterly results exceeded expectations, with earnings of $2.05 per share versus a $1.40 consensus estimate and revenue of $1.71 billion versus $1.66 billion. Analysts expect approximately $8.81 in full-year earnings per share, although the stock’s valuation remains elevated at more than 60 times earnings.
• Negative Sentiment: Insider Xiaodong Wang sold 31,028 shares for approximately $11.3 million, reducing his direct ownership by 50%. Separately, Senior Vice President Chan Lee sold 1,115 shares for about $418,000. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which lessens—but does not eliminate—their significance as a sentiment signal. BeOne Medicines insider sales

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital International Investors grew its stake in BeOne Medicines by 1.3% during the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after purchasing an additional 67,808 shares during the last quarter. Bank of America Corp DE raised its position in BeOne Medicines by 7.0% during the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after buying an additional 26,441 shares during the last quarter. Baird Financial Group Inc. lifted its stake in BeOne Medicines by 5.5% during the 2nd quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock valued at $105,148,000 after acquiring an additional 19,327 shares during the period. Candriam S.C.A. boosted its holdings in shares of BeOne Medicines by 31.7% in the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after acquiring an additional 62,470 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in shares of BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after acquiring an additional 115,601 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Weiss Ratings upgraded shares of BeOne Medicines from a “sell (d-)” rating to a “hold (c+)” rating in a report on Tuesday, September 22nd. Wolfe Research reaffirmed an “outperform” rating and issued a $370.00 price objective on shares of BeOne Medicines in a research report on Monday, August 10th. Barclays boosted their price objective on shares of BeOne Medicines from $407.00 to $415.00 and gave the stock an “overweight” rating in a research note on Thursday, September 10th. Morgan Stanley reissued an “overweight” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada cut their price target on shares of BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $404.14.

BeOne Medicines Company Profile

BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.

Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.